z-logo
open-access-imgOpen Access
Clinically Available Medicines Demonstrating Anti-Toxoplasma Activity
Author(s) -
Andrew J. Neville,
Sydney J. Zach,
Xiaofang Wang,
Joshua J. Larson,
Abigail K. Judge,
Lisa Davis,
Jonathan L. Vennerstrom,
Paul H. Davis
Publication year - 2015
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.02009-15
Subject(s) - toxoplasmosis , sulfadiazine , toxoplasma gondii , disease , pyrimethamine , medicine , drug , immunology , regimen , biology , pharmacology , antibiotics , malaria , microbiology and biotechnology , chloroquine , antibody
Toxoplasma gondii is an apicomplexan parasite of humans and other mammals, including livestock and companion animals. While chemotherapeutic regimens, including pyrimethamine and sulfadiazine regimens, ameliorate acute or recrudescent disease such as toxoplasmic encephalitis or ocular toxoplasmosis, these drugs are often toxic to the host. Moreover, no approved options are available to treat infected women who are pregnant. Lastly, no drug regimen has shown the ability to eradicate the chronic stage of infection, which is characterized by chemoresistant intracellular cysts that persist for the life of the host. In an effort to promote additional chemotherapeutic options, we now evaluate clinically available drugs that have shown efficacy in disease models but which lack clinical case reports. Ideally, less-toxic treatments for the acute disease can be identified and developed, with an additional goal of cyst clearance from human and animal hosts.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom